As a New Covid-19 Treatment Arrives, Hospitals Scramble to Solve Logistical and Ethical Challenges
November 20, 2020
(STAT News) – When the federal government started handing out a newly authorized Covid-19 treatment last week, some hospitals weren’t sure they should accept their share. On the surface, it sounded crazy. Decline a medication that might keep patients from getting severely ill? But like so many other pandemic-time medical decisions, this one offered only flawed choices. The medication is bamlanivimab, Eli Lilly’s monoclonal antibody, and it’s meant for keeping high-risk patients out of the hospital. But its use comes with a Venn diagram of difficulties.